Inside 340B Report

340B Report
  • ٥٫٠ (٤)
  • طب
  • يتم التحديث كل أسبوعين

Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.

  1. ٩ فبراير

    Episode 33: 340B Hits Capitol Hill, HRSA Withdraws Rebate Pilot, Dark Money Groups Target Statehouses

    In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and Luke Zarzecki, 340B Report's new national correspondent, break down the latest in 340B news, including 340B legislative developments on Capitol Hill and statehouses—and the role of dark money campaigns trying to shape the message. The team also discusses the Health Resources and Services Administration's major decision to formally withdraw its 340B rebate model pilot and what that could mean for the future of drugmaker-backed efforts to pursue 340B rebates.    Key Topics Covered: Capitol Hill Happenings Shannon, Luke and Will highlight the latest 340B-related happenings in Congress. Shannon discusses a new bipartisan U.S. House bill that aims to prevent federally qualified health centers from being included in any 340B rebate models and previews a yet-to-be introduced bill that would expand similar protections to other 340B covered entities, but not major hospitals. Luke provides an update on the bipartisan U.S. Senate group working on the SUSTAIN 340B Act, including what the final legislation could look like and the reported issues stalling its introduction. Shannon also offers a recap of the recently enacted federal spending package and how it's expected to affect 340B stakeholders. Meanwhile, Will discusses Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy's (R-La.) recent inquiries into 340B prime vendor Apexus as part of his broader probe into the 340B program. Rebate Model Update Will discusses the federal government's recent filing formally withdrawing its controversial 340B rebate pilot proposal and agreeing to new procedural guardrails if it attempts to implement a different 340B rebate model in the future. He then details the hospital lawsuit that led federal courts to block implementation of the 340B rebate pilot before it took effect on Jan. 1. Will also discusses what the outcome of this litigation could mean for the future of 340B rebates.  States Eye 340B Bills   Will shares new developments from statehouses in Illinois, Michigan, Kansas and Virginia, where lawmakers are considering 340B contract pharmacy access legislation, 340B provider reporting bills—or both. He also breaks down 340B Report's recent coverage of the tactics of new dark multiple new money efforts opposing 340B contract pharmacy legislation in multiple states. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship.  Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٣٠ من الدقائق

  2. ٢٦ يناير

    Episode 32: 340B Rebate Pilot Appeal Pulled, House Advances Health Spending Bill, Luke Joins the Team

    In this episode, Associate Editors and Senior Writers Shannon Young and Will Newton join Luke Zarzecki, 340B Report's new national correspondent, in breaking down the latest in 340B news, including the Department of Health and Human Services' (HHS) move to officially drop its appeal in a case that halted the 340B rebate pilot program and a new federal spending bill that includes funding for key departments overseeing the 340B program, as well as for community health centers. They also discuss new drugmaker 340B contract pharmacy and maximum fair price (MFP) policies, and Luke introduces himself. Key Topics Covered: Rebate Case Update Will provides the latest on the 340B rebate debate, including HHS' decision to drop its appeal of a Maine federal judge's injunction halting the agency's 340B rebate pilot program. That means HHS still cannot implement its 340B rebate pilot as originally planned. But, as Will notes, it does not mean the broader debate over 340B rebates is settled. He shares that attorneys who have represented both 340B providers and the drug industry do not expect drugmakers or HHS to abandon their efforts to pursue 340B rebate models. Federal Funding Package Shannon and Luke break down a new bipartisan congressional health care package and what it could mean for the 340B program. Shannon discusses a U.S. House-approved spending bill and how much it allocated for key agencies that oversee the 340B program. She also details the highly anticipated funding figures for community health centers, which are largely funded by the federal government, and notes that it doesn't include a Trump administration proposal to move 340B program oversight from the Health Resources and Services Administration to the Centers for Medicare and Medicaid Services. Luke discusses the pharmacy benefit manager (PBM) reform provisions included in the legislation and their 340B implications. Shannon also notes that congressional leaders, who authored the appropriations bill, signaled concerns with the 340B rebate pilot program and requested an update from HRSA within one month in a bipartisan document released in conjunction with the spending package. Drugmaker Policies Will and Shannon discuss recent drugmaker policy developments. Will details Eli Lilly's new policy that would require all covered entities to submit claims data on 340B utilization at in-house pharmacies in a major shift that drew strong provider backlash. Shannon discusses Johnson & Johnson's interim plan to address "deduplication" between 340B discounts and the MFP without the 340B rebate pilot. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٢٢ من الدقائق

  3. ١٢ يناير

    Episode 31: Behind the 340B Rebate Pilot Pause and Reading the 2026 Legislative Tea Leaves

    In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton in breaking down the latest in 340B news, including a Maine federal judge's ruling that halted the government's 340B rebate model pilot rollout—and subsequent appeals court actions. They also discuss what 340B stakeholders can expect from statehouses and Congress on the legislative front in 2026. Key Topics Covered: Rebate Pilot Paused Shannon, Will and Ted provide an overview of the American Hospital Association's lawsuit challenging the Department of Health and Human Services and Health Resources Administration's 340B rebate model pilot program, which was set to begin on Jan. 1. Shannon breaks down the Dec. 19 oral arguments held in Portland, Maine, that she covered, while Will discusses the judge's decision to temporarily halt the program and the government's efforts to appeal the ruling. Ted offers perspectives on how the litigation could unfold in the coming months and its implications. Actions in Another 340B Rebate Case Will provides an update on separate 340B rebate-related litigation before a Washington, D.C. federal appeals court. He explains why this case, which deals with broader legal questions about statutory authority over 340B rebates, is different from the hospital lawsuit in Maine, which is an administrative law case dealing specifically with the government's 340B rebate pilot. 2026 Legislative Agenda Shannon discusses what 340B stakeholders can expect to see on Capitol Hill in 2026, including U.S. Rep. Brett Guthrie's (R-Ky.) recent comments about prescription drug policy reforms at an early January GOP retreat. Will breaks down the latest 340B legislative activity in multiple statehouses, including the first contract pharmacy access bills of 2026 in Washington and Florida, as well as the growing number of provider reporting bills expected in the coming year. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Follow Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Verity Solutions. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٢٦ من الدقائق

  4. ٠٥‏/١٢‏/٢٠٢٥

    Episode 30: Hospital 340B Rebate Pilot Lawsuit, HRSA Webinar Issues, Key CMS Policy Updates

    In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton breaking down the latest in 340B news, including a new hospital lawsuit aiming to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot, HRSA's recent webinar about that program, key regulatory updates on Medicare negotiated drug prices and a finalized hospital outpatient rule with significant implications for 340B hospitals and other stakeholders. Key Topics Covered: Hospitals Continue to Oppose Rebate Pilot Will breaks down a hospital group's new lawsuit urging a Maine federal district court to block HRSA from implementing its 340B rebate pilot ahead of its Jan. 1, 2026 launch. He also provides an update on separate 340B rebate litigation before a Washington, D.C. federal appeals court. Shannon highlights a new letter from a different national hospital group urging HRSA to address key concerns with the pilot. Technical Issues Disrupt HRSA's Rebate Webinar Will explains the technical issues that hampered HRSA's highly anticipated Dec. 4 webinar on its 340B rebate pilot program, preventing many stakeholders from joining. He then shares details of the second half of HRSA's webinar that 340B Report was able to access and notes 340B Report will provide additional coverage of the full webinar once it becomes available. CMS Lists New Negotiated Medicare Prices, Finalizes OPPPS Rule Shannon breaks down the Centers for Medicare and Medicaid Services' (CMS) late-November release of  the "maximum fair price" (MFP) it will pay for 15 high-cost Medicare Part D drugs starting in 2027, and how those negotiated prices are expected to compare to the drugs' 340B ceiling prices. She and Ted also discuss 340B provider advocates' concerns with CMS' finalized 2026 Hospital Outpatient Prospective Payment System (OPPS) rule, which includes a Medicare drugs acquisition cost survey and plan to accelerate outpatient payment cuts to offset previous 340B hospital lump sum repayments. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by PharmaForce. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٢٢ من الدقائق

  5. ٢١‏/١١‏/٢٠٢٥

    Episode 29: One Last 340B Rebate Plan, Litigation Heats Up, Truzo Enters the Chat

    In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) approval of the final drugmaker 340B rebate pilot plan; oral arguments in a key federal court case centered on 340B rebates; and Kalderos' official entrance into the 340B contract pharmacy claims clearinghouse space. Key Topics Covered: Final Rebate Pilot Model Plans Approved, Additional Details Unveiled Will provides an in-depth look at HRSA's recent approval of Novartis' 340B rebate plan for Entresto—the final drug eligible for the upcoming  pilot program. He also explains provider concerns about the pilot's rollout—including how manufacturers and their vendor defined the claims data field "340B ID"—and HRSA's response seeking to quell those concerns. Appeals Court Hears Oral Arguments in Rebate Case Will discusses oral arguments he attended at a Washington, D.C., federal appeals court that could shape the future of 340B rebates, including HRSA's rebate pilot. Attorneys for the drug industry, the federal government and trade group 340B Health debated who—if anyone—has authority to decide whether drugmakers can offer 340B pricing through a rebate. Will notes that all three sides faced tough questioning from the judges, who appeared well-versed in the nuances of the 340B program. 1st Drugmaker Transitions to Kalderos' Truzo Platform Shannon breaks down the significance of drugmaker Alkermes' recent decision to transition its 340B contract pharmacy policy administration from Second Sight Solutions' 340B ESP platform to Kalderos' Truzo clearinghouse—making it the first drug manufacturer to do so. She also discusses the pushback the Alkermes' short timeline for the shift, which will go live Dec. 1, drew from 340B provider advocates. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٢٤ من الدقائق

  6. ٠٧‏/١١‏/٢٠٢٥

    Episode 28: Drugmaker Rebate Pilot Plans Unveiled, Mixed Decisions on Contract Pharmacy Laws, VA's 340B Election Win

    In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) recent approval of drugmaker 340B rebate pilot plans—and the reactions they sparked; major court actions affecting Oklahoma and Colorado's 340B contract pharmacy access laws; and what Abigail Spanberger's (D) Virginia gubernatorial win could mean for 340B policy in that state. Key Topics Covered: Rebate Pilot Model Plans Approved, Unveiled Will provides an in-depth look at the manufacturer rebate pilot plans that HRSA approved, as well as provider frustrations over the pilot's rollout. Shannon breaks down the contrasting reactions to HRSA's plan approvals. 340B providers panned the move and the drug industry embraced it, urging that the model be expanded. She also teases a Dec. 15 340B Report subscriber-only webinar that will focus on the rebate pilot model's implementation.  Federal Courts Block Oklahoma's Contract Pharmacy Law, Back Colorado's Will discusses a pair of conflicting federal district court rulings on 340B contract pharmacy access laws in two states. One judge blocked Oklahoma from enforcing its law while the drug industry litigation plays out, while a different judge denied AbbVie's bid to block enforcement of Colorado's statute. Despite the Oklahoma federal court's ruling, Shannon notes that some drugmakers are exempting covered entities in that state from their contract pharmacy restrictions. Virginia's Gubernatorial Election Implications Shannon breaks down how Spanberger's recent gubernatorial win could bolster advocates' efforts to enact 340B contract pharmacy protections in Virginia. She and Ted discuss Spanberger's leadership on 340B issues in Congress and how the Democrat made prescription drug pricing a key tenet of her 2025 campaign for governor. They also compare Spanberger's actions on 340B to outgoing Gov. Glenn Youngkin (R), who vetoed a widely supported, bipartisan 340B contract pharmacy access bill in 2024 after pressure from a dark-money group. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٣١ من الدقائق

  7. ٢٤‏/١٠‏/٢٠٢٥

    Episode 27: HELP 340B Hearing Surprises, Grantees Conference Takeaways & Rebate Pilot Webinar Recap

    In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Senate Health, Education, Labor and Pensions (HELP) Committee's recent hearing on 340B, key takeaways from the 340B Grantees Fall Conference in Atlanta and 340B Report's recent webinar on the Health Resources and Services Administration's (HRSA) 340B rebate pilot and where we may be headed next on that controversial proposal. Key Topics Covered: Senate HELP Committee Mixes 340B Criticisms and Support Shannon and Will provide an in-depth look at the Senate HELP Committee's Oct. 23 hearing on the 340B program, which occurred despite an ongoing federal government shutdown. Shannon discusses the dark money anti-340B campaign now underway in Washington, D.C., and how many provider advocates were pleasantly surprised about how the hearing went. Will explains that while HELP Committee Chair Bill Cassidy (R-La.) reiterated familiar 340B criticisms, many lawmakers from both parties defended the program's importance to providers. He also notes that the hearing often veered off topic, with many Democrats criticizing the government shutdown and health care cuts. Ted also discusses the growing momentum for a bipartisan group of senators' draft bill, the SUSTAIN 340B Act.  He notes that multiple lawmakers expressed support for that effort, including longtime 340B critic Cassidy. Ted also shares insights into the status of the SUSTAIN Act and what might be included in the legislation. Takeaways from 340B Grantees Conference in Atlanta and Industry Conference in NYC Ted and Will discuss their recent trip to Atlanta for the 340B Grantees Fall Conference, where they each moderated panels. Will discusses his panel on state 340B legislative activity and shares providers' concerns that drugmakers could use the 340B program as a bargaining chip in negotiations with the Trump administration on things like direct-to-consumer drug pricing and pharmaceutical tariffs. Ted discusses continued provider concerns with the HRSA's 340B rebate pilot proposal and shares insights on potential 340B negotiations with the Trump administration, which he heard at a separate conference in New York City that had a strong drug industry presence. 340B Report's Rebate Pilot Webinar and Rumblings  Shannon highlights 340B Report's recent subscriber-only webinar on HRSA's 340B rebate pilot proposal, which focused on key implementation concerns and included a lively debate on the rebate proposal's merits. Ted also shares what he is hearing about the status of the rebate model. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs, and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٢٦ من الدقائق

  8. ١٠‏/١٠‏/٢٠٢٥

    Episode 26: Govt. Shutdown's Impact on 340B, Rebate Pilot Concerns Grow, Pfizer Draws Headlines

    In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the ongoing federal government shutdown's impact on 340B operations, the latest in the 340B rebate debate and a large drugmaker's move to tighten 340B restrictions on certain hospitals that it believes are not complying with the company's current contract pharmacy policy. Key Topics Covered: Federal Government Shutdown Could Affect 340B Program Operations Shannon explains how the federal government shutdown has led to furloughs at the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs—and what that could mean for stakeholders if the shutdown drags on. She also discusses how the shutdown could impact a key upcoming deadline in HRSA's 340B rebate pilot program. Meanwhile, Ted shares his thoughts on politically-charged language about the shutdown that appeared on HRSA's website and the shutdown's real world effects on the HRSA staff and other federal workers. 340B Rebate Pilot Concerns and Upcoming Exclusive 340B Report Webinar Will discusses 340B stakeholders' continued implementation concerns with HRSA's controversial 340B rebate pilot program, including potentially significant financial and administrative burdens for providers. Will and Ted also preview 340B Report's exclusive, subscriber-only webinar on the biggest implementation questions for 340B stakeholders, which will take place on Oct. 15 and include a panel of experts from across the 340B supply chain. Pfizer Tightens 340B Restrictions, Makes Headlines with 'MFN' Move Shannon discusses Pfizer's recent move informing certain 340B hospitals that they could lose their approved one contract pharmacy exemption registered with industry vendor 340B ESP as of Nov. 1. She also explains Pfizer's headline-grabbing move to offer its drugs to Medicaid at a "most favored nation" price and launch a direct-to-consumer prescription drug platform. Shannon discusses why industry observers don't think it will have as significant an impact as it has been heralded by the White House and Pfizer executives. And why some stakeholders view those moves as undermining the drug industry's arguments that 340B drives higher drug prices. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Verity Solutions. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

    ٢٥ من الدقائق
مشاهدة الكل (٣٤)

التقييمات والمراجعات

٥
من ٥
‫٤ من التقييمات‬

حول

Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.

المعلومات

  • صناع العمل
    340B Report
  • سنوات النشاط
    ٢٠٢٤ - ٢٠٢٦
  • الحلقات
    ٣٤
  • التقييم
    ملائم
  • حقوق النشر
    © 2025
  • موقع البرنامج على الويب
    Inside 340B Report

قد يعجبك أيضًا